Hematology Frontier

With the spring breeze of April sweeping through Florence, the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025) was successfully held from March 30…

The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025) was held from March 30 to April 2 in Florence, Italy. As one of the…

On March 30, the city of Florence—birthplace of the Renaissance—welcomed the grand opening of the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025). As…

On March 30, the city of Florence—birthplace of the Renaissance—welcomed the grand opening of the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025). As…

At the 2025 EBMT Annual Meeting, cord blood transplantation (UCBT) emerged as a transformative strategy in the treatment of pediatric hematologic malignancies. Hematopoietic stem cell transplantation (HSCT) remains a life-saving therapy, and UCBT is gaining attention for its unique clinical advantages. During the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025) held in Florence, Italy, Hematology Frontier invited Prof. Fang Liu from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to share insights into the current role of transplantation in pediatric hematologic malignancies. She also highlighted her team’s latest findings in UCBT and discussed significant developments in the field of pediatric transplantation presented at the conference.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a cornerstone in the treatment of various hematologic diseases. However, several peri-transplant challenges persist, particularly regarding the optimal timing of transplantation, the role of consolidation therapy, and maintenance strategies. At the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025), the transplant team from Ruijin Hospital, Shanghai JiaoTong University School of Medicine, presented several notable studies. Among them, three studies—B254, B259, and A001—focused on comprehensive leukemia management and transplant integration, drawing significant attention from the clinical community. Hematology Frontier invited Prof. Xiaoxia Hu to provide in-depth commentary on these research findings.

The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025) was held from March 30 to April 2 in the historic city of Florence, Italy. As one of the most influential global events in the field of hematology, the Annual Meeting gathered over 5,000 experts and scholars from around the world to explore cutting-edge advances in hematopoietic stem cell transplantation (HSCT) and cellular therapy.At the Annual Meeting , Hematology frontier had the honor of speaking with Professor Qifa Liu of the Nanfang Hospital, Southern Medical University. Prof. Liu shared his insights on the latest progress in graft-versus-host disease (GVHD) prevention and treatment, particularly focusing on the innovative applications of mesenchymal stem cells (MSCs) and fecal microbiota transplantation (FMT). He also reflected on the impact of this year’s Annual Meeting on ongoing and future clinical research directions.

Hematopoietic stem cell transplantation (HSCT) remains a curative treatment for numerous hematologic disorders. Despite its life-saving potential, many clinical challenges persist, particularly concerning patient selection, transplant timing, and long-term management. To enhance academic exchange and practical insights in the field of transplantation, Hematology Frontier launched the special feature "Transplantation Pathways Spotlight" during the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025). This column brings together leading experts from China and abroad to discuss full-cycle transplant care, from pre-transplant assessment through to long-term recovery, aiming to establish an integrated and forward-looking framework for clinical transplantation.

Hematopoietic stem cell transplantation (HSCT) remains a cornerstone therapy for hematologic diseases. However, despite its curative potential, many clinical challenges persist. To promote academic exchange and practical innovation in the field of transplantation, Hematology Frontier launched the “Transplantation Pathways Spotlight” during the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2025). This column invites renowned transplantation teams from China and abroad to focus on full-cycle transplant care—from precise pre-transplant assessment to long-term post-transplant recovery—building a comprehensive, integrated transplant management framework.

At the 51st Annual Meeting of EBMT, Dr. Eduardo Rodríguez-Arbolí presented important long-term data from an ALWP-EBMT study focusing on patients with acute myeloid leukemia (AML) who underwent haploidentical HSCT…